Mesenchymal stem cell therapy for liver transplantation: clinical progress and immunomodulatory properties.
Cell therapy
Immunoregulation
Liver transplantation
Mesenchymal stem cells
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
05
07
2024
accepted:
16
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Although liver transplantation (LT) is an effective strategy for end-stage liver diseases, the shortage of donor organs and the immune rejection hinder its widespread implementation in clinical practice. Mesenchymal stem cells (MSCs) transplantation offers a promising approach for patients undergoing liver transplantation due to their immune regulatory capabilities, hepatic protection properties, and multidirectional differentiation potential. In this review, we summarize the potential applications of MSCs transplantation in various LT scenarios. MSCs transplantation has demonstrated effectiveness in alleviating hepatic ischemia-reperfusion injury, enhancing the viability of liver grafts, preventing acute graft-versus-host disease, and promoting liver regeneration in split LT therapy. We also discuss the clinical progress, and explore the immunomodulatory functions of MSCs in response to both adaptive and innate immune responses. Furthermore, we emphasize the interactions between MSCs and different immune cells, including T cells, B cells, plasma cells, natural killer cells, dendritic cells, Kupffer cells, and neutrophils, to provide new insights into the immunomodulatory properties of MSCs in adoptive cell therapy.
Identifiants
pubmed: 39334441
doi: 10.1186/s13287-024-03943-6
pii: 10.1186/s13287-024-03943-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
320Subventions
Organisme : National Natural Science Foundation of Fujian
ID : 2023J011465
Organisme : the Scientific Research Youth Project of Fujian Health Committee
ID : 2022QNA001
Organisme : Startup Fund for Scientific Research, Fujian Medical University
ID : 2022QH1284
Informations de copyright
© 2024. The Author(s).
Références
Mohammadi D. The liver transplant:a tricky, tricky thing. Lancet Gastroenterol. 2016;1:181.
Jung DH, Ikegami T, Balci D, Bhangui P. Biliary reconstruction and complications in living donor liver transplantation. Int J Surg. 2020;82S:138–44.
pubmed: 32387205
doi: 10.1016/j.ijsu.2020.04.069
Khalil A, Quaglia A, Gélat P, Saffari N, Rashidi H, Davidson B. New developments and challenges in liver transplantation. J Clin Med. 2023;12:5586.
pubmed: 37685652
pmcid: 10488676
doi: 10.3390/jcm12175586
Ten Dam MJM, Frederix GWJ, Ten Ham RMT, van der Laan LJW, Schneeberger K. Toward transplantation of liver organoids: from biology and ethics to cost-effective therapy. Transplantation. 2023;107:1706–17.
pubmed: 36757819
pmcid: 10358442
doi: 10.1097/TP.0000000000004520
Ivanics T, Abreu P, De Martin E, Sapisochin G. Changing trends in liver transplantation: challenges and solutions. Transplantation. 2021;105:743–56.
pubmed: 32910093
doi: 10.1097/TP.0000000000003454
Zhang C, Huang J, An W. Hepatic stimulator substance resists hepatic ischemia/reperfusion injury by regulating Drp1 translocation and activation. Hepatology. 2017;66:1989–2001.
pubmed: 28646508
doi: 10.1002/hep.29326
Zhao H, Yang Y, Si X, Liu H, Wang H. The role of pyroptosis and autophagy in ischemia reperfusion injury. Biomolecules. 2022;12:1010.
pubmed: 35883566
pmcid: 9313059
doi: 10.3390/biom12071010
Zhou W, Zhong Z, Lin D, Liu Z, Zhang Q, Xia H, et al. Hypothermic oxygenated perfusion inhibits HECTD3-mediated TRAF3 polyubiquitination to alleviate DCD liver ischemia-reperfusion injury. Cell Death Dis. 2021;12(2):211.
pubmed: 33627626
pmcid: 7904838
doi: 10.1038/s41419-021-03493-2
Guo Z, Zhao Q, Jia Z, Huang C, Wang D, Ju W, et al. A randomized-controlled trial of ischemia-free liver transplantation for end-stage liver disease. J Hepatol. 2023;79:394–402.
pubmed: 37086919
doi: 10.1016/j.jhep.2023.04.010
Press AT, Ungelenk L, Medyukhina A, Pennington SA, Nietzsche S, Kan C, et al. Sodium thiosulfate refuels the hepatic antioxidant pool reducing ischemia-reperfusion-induced liver injury. Free Radic Biol Med. 2023;204:151–60.
pubmed: 37105418
doi: 10.1016/j.freeradbiomed.2023.04.012
Montano-Loza AJ, Rodriguez-Peralvarez ML, Pageaux GP, Sanchez-Fueyo A, Feng S. Liver transplantation immunology: immunosuppression, rejection, and immunomodulation. J Hepatol. 2023;78:1199–215.
pubmed: 37208106
doi: 10.1016/j.jhep.2023.01.030
Levitsky J, Goldberg D, Smith AR, Mansfield SA, Gillespie BW, Merion RM, et al. Acute rejection increases risk of graft failure and death in recent liver transplant recipients. Clin Gastroenterol Hepatol. 2017;15:584–93.
pubmed: 27567694
doi: 10.1016/j.cgh.2016.07.035
Charlton M, Levitsky J, Aqel B, O’Grady J, Hemibach J, Rinella M, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients. Transplantation. 2018;102:727–43.
pubmed: 29485508
doi: 10.1097/TP.0000000000002147
Tan PS, Muthiah MD, Koh T, Teoh YL, Chan A, Kow A, et al. Asian liver transplant network clinical guidelines on immunosuppression in liver transplantation. Transplantation. 2019;103:470–80.
pubmed: 30422953
doi: 10.1097/TP.0000000000002532
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.
pubmed: 16923606
doi: 10.1080/14653240600855905
Lu X, Guo H, Wei X, Lu D, Shu W, Song Y, et al. Current status and prospect of delivery vehicle based on mesenchymal stem cell-derived exosomes in liver diseases. Int J Nanomed. 2023;18:2873–90.
doi: 10.2147/IJN.S404925
Schrodt MV, Behan-Bush RM, Liszewski JN, Humpal-Pash ME, Boland LK, Scroggins SM, et al. Efferocytosis of viable versus heat-inactivated MSC induces human monocytes to distinct immunosuppressive phenotypes. Stem Cell Res Ther. 2023;14(1):206.
pubmed: 37592321
pmcid: 10433682
doi: 10.1186/s13287-023-03443-z
Fu Y, Wang Y, Liang L, Gu M, Gao Y, Feng L. Mesenchymal stem cell utilization for in vitro donor liver machine perfusion preservation: current status and future directions. Stem Cells Transl Med. 2023;12:665–75.
pubmed: 37643740
pmcid: 10552689
doi: 10.1093/stcltm/szad053
Zuo H, Wang Y, Yuan M, Zheng W, Tian X, Pi Y, et al. Small extracellular vesicles from HO-1-modified bone marrow-derived mesenchymal stem cells attenuate ischemia-reperfusion injury after steatotic liver transplantation by suppressing ferroptosis via miR-214-3p. Cell Signal. 2023;109:110793.
pubmed: 37414107
doi: 10.1016/j.cellsig.2023.110793
Liu J, Man K. Mechanistic insight and clinical implications of ischemia/reperfusion injury post liver transplantation. Cell Mol Gastroenterol Hepatol. 2023;15:1463–74.
pubmed: 36940849
pmcid: 10160787
doi: 10.1016/j.jcmgh.2023.03.003
Xu C, Fang X, Lu B, Song Y, Shu W, Lu Z, et al. Human umbilical cord mesenchymal stem cells alleviate fatty liver ischemia-reperfusion injury by activating autophagy through upregulation of IFNγ. Cell Biochem Funct. 2024;42:e4040.
pubmed: 38850132
doi: 10.1002/cbf.4040
Shang LC, Wang M, Liu Y, Zhu X, Wang S. MSCs ameliorate hepatic IR injury by modulating phenotypic transformation of kupffer cells through Drp-1 dependent mitochondrial dynamics. Stem Cell Rev Rep. 2023;19:1965–80.
pubmed: 37243829
doi: 10.1007/s12015-023-10566-6
Zheng J, Chen L, Lu T, Zhang Y, Sui X, Li Y, et al. MSCs ameliorate hepatocellular apoptosis mediated by PINK1-dependent mitophagy in liver ischemia/reperfusion injury through AMPKα activation. Cell Death Dis. 2020;11:256.
pubmed: 32312955
pmcid: 7171190
doi: 10.1038/s41419-020-2424-1
Chen K, Obara H, Matsubara Y, Fukuda K, Yagi H, Ono-Uruga Y, et al. Adipose-derived mesenchymal stromal/stem cell line prevents hepatic ischemia/reperfusion injury in rats by inhibiting inflammasome activation. Cell Transpl. 2022;31:9636897221089629.
doi: 10.1177/09636897221089629
Li S, Zheng X, Li H, Zheng J, Chen X, Liu W, et al. Mesenchymal stem cells ameliorate hepatic ischemia/reperfusion injury via inhibition of neutrophil recruitment. J Immunol Res. 2018;2018:7283703.
pubmed: 30622980
pmcid: 6304871
doi: 10.1155/2018/7283703
Wu R, Fan X, Wang Y, Shen M, Zheng Y, Zhao S, et al. Mesenchymal stem cell-derived extracellular vesicles in liver immunity and therapy. Front Immunol. 2022;13:833878.
pubmed: 35309311
pmcid: 8930843
doi: 10.3389/fimmu.2022.833878
Wu L, Tian X, Zuo H, Zheng W, Li X, Yuan M, et al. Mir-124-3p delivered by exosomes from heme oxygenase-1 modified bone marrow mesenchymal stem cells inhibits ferroptosis to attenuate ischemia-reperfusion injury in steatotic grafts. J Nanobiotechnol. 2022;20:196.
doi: 10.1186/s12951-022-01407-8
Lu T, Zhang J, Cai J, Xiao J, Sui X, Yuan X, et al. Extracellular vesicles derived from mesenchymal stromal cells as nanotherapeutics for liver ischaemia-reperfusion injury by transferring mitochondria to modulate the formation of neutrophil extracellular traps. Biomaterials. 2022;284:121486.
pubmed: 35447404
doi: 10.1016/j.biomaterials.2022.121486
Zhang Q, Liu X, Piao C, Jiao Z, Ma Y, Wang Y, et al. Effect of conditioned medium from adipose derived mesenchymal stem cells on endoplasmic reticulum stress and lipid metabolism after hepatic ischemia reperfusion injury and hepatectomy in swine. Life Sci. 2022;289:120212.
pubmed: 34896163
doi: 10.1016/j.lfs.2021.120212
Li X, Wu L, Tian X, Zheng W, Yuan M, Tian X, et al. miR-29a-3p in exosomes from heme oxygenase-1 modified bone marrow mesenchymal stem cells alleviates steatotic liver ischemia-reperfusion injury in rats by suppressing ferroptosis via iron responsive element binding protein 2. Oxid Med Cell Longev. 2022;2022:6520789.
pubmed: 35720183
pmcid: 9203237
Zheng J, Lu T, Zhou C, Cai J, Zhang X, Liang J, et al. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells protect liver ischemia/reperfusion injury by reducing CD154 expression on CD4 + T cells via CCT2. Adv Sci. 2020;7:1903746.
doi: 10.1002/advs.201903746
Cao H, Wu L, Tian X, Zheng W, Yuan M, Li X, et al. HO-1/BMMSC perfusion using a normothermic machine perfusion system reduces the acute rejection of DCD liver transplantation by regulating NKT cell co-inhibitory receptors in rats. Stem Cell Res Ther. 2021;12:587.
pubmed: 34819139
pmcid: 8611848
doi: 10.1186/s13287-021-02647-5
Li J, Peng Q, Yang R, Li K, Zhu P, Zhu Y, et al. Application of mesenchymal stem cells during machine perfusion: an emerging novel strategy for organ preservation. Front Immunol. 2021;12:713920.
pubmed: 35024039
pmcid: 8744145
doi: 10.3389/fimmu.2021.713920
Yang L, Cao H, Sun D, Hou B, Lin L, Shen ZY, et al. Bone marrow mesenchymal stem cells combine with normothermic machine perfusion to improve rat donor liver quality-the important role of hepatic microcirculation in donation after circulatory death. Cell Tissue Res. 2020;381:239–54.
pubmed: 32347385
pmcid: 7369267
doi: 10.1007/s00441-020-03202-z
Sasajima H, Miyagi S, Yamada S, Kakizaki Y, Kamei T, Unno M, et al. Cytoprotective effects of mesenchymal stem cells during liver transplantation from donors after cardiac death in swine. Transpl Proc. 2020;52:1891–900.
doi: 10.1016/j.transproceed.2020.01.165
Tian Y, Wang J, Wang W, Ding Y, Sun Z, Zhang Q, et al. Stem Cell Res Ther. 2016;7:157.
pubmed: 27788674
pmcid: 5084468
doi: 10.1186/s13287-016-0416-y
Newell LF, Dunlap J, Gatter K, Bagby GC, Press RD, Cook RJ, et al. Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations. Am J Transpl. 2021;21:3894–906.
doi: 10.1111/ajt.16635
Kneifel F, Vogel T, Bormann E, Becker F, Houben P, Flammang I, et al. Graft-versus-host disease following liver transplantation: a systematic review of literature. Hepatol Commun. 2023;7:e0260.
pubmed: 37755878
pmcid: 10531273
doi: 10.1097/HC9.0000000000000260
Xia X, Chen W, Ma T, Xu G, Liu H, Liang C, et al. Mesenchymal stem cells administered after liver transplantation prevent acute graft-versus-host disease in rats. Liver Transpl. 2012;18:696–706.
pubmed: 22344929
doi: 10.1002/lt.23414
Goldaracena N, Cullen JM, Kim DS, Ekser B, Halazun KJ. Expanding the donor pool for liver transplantation with marginal donors. Int J Surg. 2020;82S:30–5.
pubmed: 32422385
doi: 10.1016/j.ijsu.2020.05.024
Shan Y, Yu X, Du Y, Fang J, Huang J, Sun J, et al. Short-term monitoring of graft regeneration in partial liver transplantation recipients. Ann Transpl. 2023;28:e941444.
doi: 10.12659/AOT.941444
Ding HR, Wang JL, Tang ZT, Wang Y, Zhou G, Liu Y, et al. Mesenchymal stem cells improve glycometabolism and liver regeneration in the treatment of post-hepatectomy liver failure. Front Physiol. 2019;10:412.
pubmed: 31024348
pmcid: 6468048
doi: 10.3389/fphys.2019.00412
Zhang J, Gao J, Li X, Lin D, Li Z, Wang J, et al. Bone marrow mesenchymal stem cell-derived small extracellular vesicles promote liver regeneration via miR-20a-5p/PTEN. Front Pharmacol. 2023;14:1168545.
pubmed: 37305542
pmcid: 10248071
doi: 10.3389/fphar.2023.1168545
Yu Y, Yao AH, Chen N, Pu LY, Fan Y, Lv L, et al. Mesenchymal stem cells over-expressing hepatocyte growth factor improve small-for-size liver grafts regeneration. Mol Ther. 2007;15:1382–9.
pubmed: 17519892
doi: 10.1038/sj.mt.6300202
Wang R, Shen Z, Yang L, Yin M, Zheng W, Wu B, et al. Protective effects of heme oxygenase-1-transduced bone marrow-derived mesenchymal stem cells on reduced-size liver transplantation: role of autophagy regulated by the ERK/mTOR signaling pathway. Int J Mol Med. 2017;40:1537–48.
pubmed: 28901391
pmcid: 5627878
doi: 10.3892/ijmm.2017.3121
Bradstreet RW, Toledo-Pereyra LH. Role of mesenchymal stem cells in partial liver transplantation. J Surg Res. 2014;186:95–6.
pubmed: 23726236
doi: 10.1016/j.jss.2013.04.066
Casiraghi F, Perico N, Podestà MA, Todeschini M, Zambelli M, Colledan M, et al. Third-party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation: a randomized controlled trial. Am J Transpl. 2021;21:2795–809.
doi: 10.1111/ajt.16468
Shi M, Liu Z, Wang Y, Xu R, Sun Y, Zhang M, et al. A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection. Stem Cells Transl Med. 2017;6:2053–61.
pubmed: 29178564
pmcid: 5702514
doi: 10.1002/sctm.17-0134
Zhang Y, Zhang J, Yi H, Zheng J, Cai J, Chen W, et al. A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trial. Stem Cell Res Ther. 2021;12(1):244.
pubmed: 33863383
pmcid: 8050996
doi: 10.1186/s13287-021-02246-4
Zhang YC, Liu W, Fu BS, Wang GY, Li HB, Yi HM, et al. Therapeutic potentials of umbilical cord-derived mesenchymal stromal cells for ischemic-type biliary lesions following liver transplantation. Cytotherapy. 2017;19:194–9.
pubmed: 27964826
doi: 10.1016/j.jcyt.2016.11.005
Vandermeulen M, Mohamed-Wais M, Erpicum P, Delbouille MH, Lechanteur C, Briquet A, et al. Infusion of allogeneic mesenchymal stromal cells after liver transplantation: a 5-year follow-up. Liver Transpl. 2022;28:636–46.
pubmed: 34605167
doi: 10.1002/lt.26323
Detry O, Vandermeulen M, Delbouille MH, Somja J, Bletard N, Briquet A, et al. Infusion of mesenchymal stromal cells after deceased liver transplantation: a phase I-II, open-label, clinical study. J Hepatol. 2017;67:47–55.
pubmed: 28284916
doi: 10.1016/j.jhep.2017.03.001
Zhang Y, Li S, Wang G, Peng Y, Zhang Q, Li H, et al. Mesenchymal stem cells for treatment of steroid-resistant acute rejection after liver transplantation. Liver Res. 2017;1:140–5.
doi: 10.1016/j.livres.2017.07.001
Tang Q, Leung J, Peng Y, Sanchez-Fueyo A, Lozano JJ, Lam A, et al. Selective decrease of donor-reactive Tregs after liver transplantation limits Treg therapy for promoting allograft tolerance in humans. Sci Transl Med. 2022;14:eabo2628.
pubmed: 36322627
pmcid: 11016119
doi: 10.1126/scitranslmed.abo2628
Tang J, Weng R, Fang T, Zhang K, Yan X, Jin X, et al. Clinical outcomes of liver transplantation in human immunodeficiency virus/hepatitis B virus coinfected patients in China. BMC Infect Dis. 2024;24:383.
pubmed: 38589801
pmcid: 11003048
doi: 10.1186/s12879-024-09284-2
Markmann JF, Abouljoud MS, Ghobrial RM, Bhati CS, Pelletier SJ, Lu AD, et al. Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant: the ocs liver protect randomized clinical trial. JAMA Surg. 2022;157:189–98.
pubmed: 34985503
pmcid: 8733869
doi: 10.1001/jamasurg.2021.6781
Manuel O, Laager M, Hirzel C, Neofytos D, Walti LN, Hoenger G et al. Immune monitoring-guided versus fixed duration of antiviral prophylaxis against cytomegalovirus in solid-organ transplant recipients: a multicenter, randomized clinical trial. Clin Infect Dis 20247;78:312–23.
Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392–402.
pubmed: 24094322
doi: 10.1016/j.stem.2013.09.006
Wang Y, Fang J, Liu B, Shao C, Shi Y. Reciprocal regulation of mesenchymal stem cells and immune responses. Cell Stem Cell. 2022;29:1515–30.
pubmed: 36332569
doi: 10.1016/j.stem.2022.10.001
Tian Z, Chen Y, Gao B. Natural killer cells in liver disease. Hepatology. 2013;57:1654–62.
pubmed: 23111952
doi: 10.1002/hep.26115
Qu M, Cui J, Zhu J, Ma Y, Yuan X, Shi J, et al. Bone marrow-derived mesenchymal stem cells suppress NK cell recruitment and activation in PolyI:C-induced liver injury. Biochem Biophys Res Commun. 2015;466:173–9.
pubmed: 26342798
doi: 10.1016/j.bbrc.2015.08.125
Almeida CR, Caires HR, Vasconcelos DP, Barbosa MA. NAP-2 secreted by human nk cells can stimulate mesenchymal stem/stromal cell recruitment. Stem Cell Rep. 2016;6:466–73.
doi: 10.1016/j.stemcr.2016.02.012
Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 2006;107:1484–90.
pubmed: 16239427
doi: 10.1182/blood-2005-07-2775
Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008;111:1327–33.
pubmed: 17951526
doi: 10.1182/blood-2007-02-074997
Fan Y, Herr F, Vernochet A, Mennesson B, Oberlin E, Durrbach A. Human fetal liver mesenchymal stem cell-derived exosomes impair natural killer cell function. Stem Cells Dev. 2019;28:44–55.
pubmed: 30328799
doi: 10.1089/scd.2018.0015
Thomas H, Jäger M, Mauel K, Brandau S, Lask S, Flohé SB. Interaction with mesenchymal stem cells provokes natural killer cells for enhanced IL-12/IL-18-induced interferon-gamma secretion. Mediators Inflamm. 2014;2014:143463.
pubmed: 24876666
pmcid: 4021755
doi: 10.1155/2014/143463
Cui R, Rekasi H, Hepner-Schefczyk M, Fessmann K, Petri RM, Bruderek K, et al. Human mesenchymal stromal/stem cells acquire immunostimulatory capacity upon cross-talk with natural killer cells and might improve the NK cell function of immunocompromised patients. Stem Cell Res Ther. 2016;7:88.
pubmed: 27388156
pmcid: 4937587
doi: 10.1186/s13287-016-0353-9
Tacke F. Targeting hepatic macrophages to treat liver diseases. J Hepatol. 2017;66:1300–12.
pubmed: 28267621
doi: 10.1016/j.jhep.2017.02.026
Liang X, Li T, Zhou Q, Pi S, Li Y, Chen X, et al. Mesenchymal stem cells attenuate sepsis-induced liver injury via inhibiting M1 polarization of Kupffer cells. Mol Cell Biochem. 2019;452:187–97.
pubmed: 30178273
doi: 10.1007/s11010-018-3424-7
Zhang Y, Zhang X, Zhang H, Song P, Pan W, Xu P, et al. Mesenchymal stem cells derived extracellular vesicles alleviate traumatic hemorrhagic shock induced hepatic injury via IL-10/PTPN22-mediated M2 kupffer cell polarization. Front Immunol. 2022;12:811164.
pubmed: 35095903
pmcid: 8790700
doi: 10.3389/fimmu.2021.811164
You Y, Zhang J, Gong J, Chen Y, Li Y, Yang K, et al. Mesenchymal stromal cell-dependent reprogramming of Kupffer cells is mediated by TNF-α and PGE2 and is crucial for liver transplant tolerance. Immunol Res. 2015;62:292–305.
pubmed: 25982496
doi: 10.1007/s12026-015-8660-2
Yang X, Liang L, Zong C, Lai F, Zhu P, Liu Y, et al. Kupffer cells-dependent inflammation in the injured liver increases recruitment of mesenchymal stem cells in aging mice. Oncotarget. 2016;7:1084–95.
pubmed: 26716516
doi: 10.18632/oncotarget.6744
Ahn SY, Maeng YS, Kim YR, Choe YH, Hwang HS, Hyun YM. In vivo monitoring of dynamic interaction between neutrophil and human umbilical cord blood-derived mesenchymal stem cell in mouse liver during sepsis. Stem Cell Res Ther. 2020;11:44.
pubmed: 32014040
pmcid: 6998265
doi: 10.1186/s13287-020-1559-4
Wan YM, Li ZQ, Liu C, He YF, Wang MJ, Wu XN, et al. Mesenchymal stem cells reduce alcoholic hepatitis in mice via suppression of hepatic neutrophil and macrophage infiltration, and of oxidative stress. PLoS ONE. 2020;15:e0228889.
pubmed: 32045450
pmcid: 7012433
doi: 10.1371/journal.pone.0228889
Yao J, Zheng J, Cai J, Zeng K, Zhou C, Zhang J, et al. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells alleviate rat hepatic ischemia-reperfusion injury by suppressing oxidative stress and neutrophil inflammatory response. FASEB J. 2019;33:1695–710.
pubmed: 30226809
doi: 10.1096/fj.201800131RR
Jacobs R, Brandau S, Jakob M, Bruderek K, Bootz F, Giebel B, et al. Mesenchymal stem cells augment the anti-bacterial activity of neutrophil granulocytes. PLoS ONE. 2014;9:e106903.
doi: 10.1371/journal.pone.0106903
Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells. 2008;26:151–62.
pubmed: 17932421
doi: 10.1634/stemcells.2007-0416
Mahmoudi M, Taghavi-Farahabadi M, Rezaei N, Hashemi SM. Comparison of the effects of adipose tissue mesenchymal stromal cell-derived exosomes with conditioned media on neutrophil function and apoptosis. Int Immunopharmacol. 2019;74:105689.
pubmed: 31207404
doi: 10.1016/j.intimp.2019.105689
Ko E, Yoon T, Lee Y, Kim J, Park YB. ADSC secretome constrains NK cell activity by attenuating IL-2-mediated JAK-STAT and AKT signaling pathway via upregulation of CIS and DUSP4. Stem Cell Res Ther. 2023;14:329.
pubmed: 37964351
pmcid: 10648656
doi: 10.1186/s13287-023-03516-z
Park M, Kim YH, Ryu JH, Woo SY, Ryu KH. Immune suppressive effects of tonsil-derived mesenchymal stem cells on mouse bone-marrow-derived dendritic cells. Stem Cells Int. 2015;2015:106540.
pubmed: 25784940
pmcid: 4345276
doi: 10.1155/2015/106540
Wheat WH, Chow L, Kurihara JN, Regan DP, Coy JW, Webb TL, et al. Suppression of canine dendritic cell activation/maturation and inflammatory cytokine release by mesenchymal stem cells occurs through multiple distinct biochemical pathways. Stem Cells Dev. 2017;26:249–62.
pubmed: 27842458
pmcid: 6913781
doi: 10.1089/scd.2016.0199
Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood. 2009;113:6576–83.
pubmed: 19398717
doi: 10.1182/blood-2009-02-203943
Reis M, Mavin E, Nicholson L, Green K, Dickinson AM, Wang XN. Mesenchymal stromal cell-derived extracellular vesicles attenuate dendritic cell maturation and function. Front Immunol. 2018;9:2538.
pubmed: 30473695
pmcid: 6237916
doi: 10.3389/fimmu.2018.02538
Shahir M, Mahmoud Hashemi S, Asadirad A, Varahram M, Kazempour-Dizaji M, Folkerts G, et al. Effect of mesenchymal stem cell‐derived exosomes on the induction of mouse tolerogenic dendritic cells. J Cell Physiol. 2020;235:7043–55.
pubmed: 32043593
pmcid: 7496360
doi: 10.1002/jcp.29601
Lu Z, Meng S, Chang W, Fan S, Xie J, Guo F, et al. Mesenchymal stem cells activate notch signaling to induce regulatory dendritic cells in LPS-induced acute lung injury. J Transl Med. 2020;18:241.
pubmed: 32546185
pmcid: 7298963
doi: 10.1186/s12967-020-02410-z
Wang Y, Zhang A, Ye Z, Xie H, Zheng S. Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion. Transpl Proc. 2009;41:4352–6.
doi: 10.1016/j.transproceed.2009.08.072
Tang J, Yang R, Lv L, Yao A, Pu L, Yin A, et al. Transforming growth factor-β-expressing mesenchymal stem cells induce local tolerance in a rat liver transplantation model of acute rejection. Stem Cells. 2016;34:2681–92.
pubmed: 27333806
doi: 10.1002/stem.2437
Mittal SK, Cho W, Elbasiony E, Guan Y, Foulsham W, Chauhan SK. Mesenchymal stem cells augment regulatory T cell function via CD80-mediated interactions and promote allograft survival. Am J Transpl. 2022;22:1564–77.
doi: 10.1111/ajt.17001
Yang R, Gao H, Chen L, Fang N, Chen H, Song G, et al. Effect of peripheral blood-derived mesenchymal stem cells on macrophage polarization and Th17/Treg balance in vitro. Regen Ther. 2020;14:275–83.
pubmed: 32455158
pmcid: 7232039
doi: 10.1016/j.reth.2020.03.008
Zhang D, Lin Y, Li Y, Zhao D, Du M. Mesenchymal stem cells enhance Treg immunosuppressive function at the fetal-maternal interface. J Reprod Immunol. 2021;148:103366.
pubmed: 34492568
doi: 10.1016/j.jri.2021.103366
Court AC, Le-Gatt A, Luz-Crawford P, Parra E, Aliaga-Tobar V, Bátiz LF, et al. Mitochondrial transfer from MSCs to T cells induces Treg differentiation and restricts inflammatory response. EMBO Rep. 2020;21:e48052.
pubmed: 31984629
pmcid: 7001501
doi: 10.15252/embr.201948052
Feng X, Feng B, Zhou J, Yang J, Pan Q, Yu J, et al. Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells. Hepatology. 2024. https://doi.org/10.1097/HEP.0000000000000831 .
doi: 10.1097/HEP.0000000000000831
pubmed: 39178365
Che N, Li X, Zhou S, Liu R, Shi D, Lu L, et al. Umbilical cord mesenchymal stem cells suppress B-cell proliferation and differentiation. Cell Immunol. 2012;274:46–53.
pubmed: 22414555
doi: 10.1016/j.cellimm.2012.02.004
Liu J, Liu Q, Chen X. The immunomodulatory effects of mesenchymal stem cells on regulatory B cells. Front Immunol. 2020;11:1843.
pubmed: 32922398
pmcid: 7456948
doi: 10.3389/fimmu.2020.01843
Li H, Deng Y, Liang J, Huang F, Qiu W, Zhang M, et al. Mesenchymal stromal cells attenuate multiple sclerosis via IDO-dependent increasing the suppressive proportion of CD5 + IL-10 + B cells. Am J Transl Res. 2019;11:5673–88.
pubmed: 31632539
pmcid: 6789281
Peng Y, Chen X, Liu Q, Zhang X, Huang K, Liu L, et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5 + regulatory B cells producing interleukin 10. Leukemia. 2015;29:636–46.
pubmed: 25034146
doi: 10.1038/leu.2014.225
Chen X, Cai C, Xu D, Liu Q, Zheng S, Liu L, et al. Human mesenchymal stem cell-treated regulatory CD23
pubmed: 31367246
pmcid: 6643430
doi: 10.7150/thno.32260
Rosado MM, Bernardo ME, Scarsella M, Conforti A, Giorda E, Biagini S, et al. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev. 2015;24:93–103.
pubmed: 25036865
doi: 10.1089/scd.2014.0155
Li H, Yu S, Liu H, Chen L, Liu H, Liu X, et al. Immunologic barriers in liver transplantation: a single-cell analysis of the role of mesenchymal stem cells. Front Immunol. 2023;14:1274982.
pubmed: 38143768
pmcid: 10748593
doi: 10.3389/fimmu.2023.1274982
Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2:141–50.
pubmed: 18371435
doi: 10.1016/j.stem.2007.11.014
Calligaris M, Zito G, Busà R, Bulati M, Iannolo G, Gallo A, et al. Proteomic analysis and functional validation reveal distinct therapeutic capabilities related to priming of mesenchymal stromal/stem cells with IFN-γ and hypoxia: potential implications for their clinical use. Front Cell Dev Biol. 2024;12:1385712.
pubmed: 38882056
pmcid: 11179434
doi: 10.3389/fcell.2024.1385712
Huang Y, Li Q, Zhang K, Hu M, Wang Y, Du L, et al. Single cell transcriptomic analysis of human mesenchymal stem cells reveals limited heterogeneity. Cell Death Dis. 2019;10:368.
pubmed: 31068579
pmcid: 6506509
doi: 10.1038/s41419-019-1583-4
Lu S, Qiao X. Single-cell profiles of human bone marrow-derived mesenchymal stromal cells after IFN-γ and TNF-α licensing. Gene. 2021;771:145347.
pubmed: 33333228
doi: 10.1016/j.gene.2020.145347
Hu Z, Li D, Wu S, Pei K, Fu Z, Yang Y, et al. Unveiling the functional heterogeneity of cytokine-primed human umbilical cord mesenchymal stem cells through single-cell RNA sequencing. Cell Biosci. 2024;14:40.
pubmed: 38532459
pmcid: 10964690
doi: 10.1186/s13578-024-01219-3
Tolstova T, Dotsenko E, Kozhin P, Novikova S, Zgoda V, Rusanov A, et al. The effect of TLR3 priming conditions on MSC immunosuppressive properties. Stem Cell Res Ther. 2023;14(1):344.
pubmed: 38031182
pmcid: 10687850
doi: 10.1186/s13287-023-03579-y
Jammes M, Contentin R, Audigié F, Cassé F, Galéra P. Effect of pro-inflammatory cytokine priming and storage temperature of the mesenchymal stromal cell (MSC) secretome on equine articular chondrocytes. Front Bioeng Biotechnol. 2023;11:1204737.
pubmed: 37720315
pmcid: 10502223
doi: 10.3389/fbioe.2023.1204737
Kota DJ, Prabhakara KS, Toledano-Furman N, Bhattarai D, Chen Q, DiCarlo B, et al. Prostaglandin E2 indicates therapeutic efficacy of mesenchymal stem cells in experimental traumatic brain injury. Stem Cells. 2017;35:1416–30.
pubmed: 28233425
doi: 10.1002/stem.2603
Lee RH, Boregowda SV, Shigemoto-Kuroda T, Bae E, Haga CL, Abbery CA, et al. TWIST1 and TSG6 are coordinately regulated and function as potency biomarkers in human MSCs. Sci Adv. 2023;9:eadi2387.
pubmed: 37948519
pmcid: 10637745
doi: 10.1126/sciadv.adi2387
Maughon TS, Shen X, Huang D, Michael AOA, Shockey WA, Andrews SH, et al. Metabolomics and cytokine profiling of mesenchymal stromal cells identify markers predictive of T-cell suppression. Cytotherapy. 2022;24:137–48.
pubmed: 34696960
doi: 10.1016/j.jcyt.2021.08.002
Yu S, Yu S, Liu H, Liao N, Liu X. Enhancing mesenchymal stem cell survival and homing capability to improve cell engraftment efficacy for liver diseases. Stem Cell Res Ther. 2023;14:235.
pubmed: 37667383
pmcid: 10478247
doi: 10.1186/s13287-023-03476-4
Yang L, Cao H, Sun D, Lin L, Zheng WP, Shen ZY, et al. Normothermic machine perfusion combined with bone marrow mesenchymal stem cells improves the oxidative stress response and mitochondrial function in rat donation after circulatory death livers. Stem Cells Dev. 2020;29(13):835–52.
pubmed: 32253985
pmcid: 7336881
doi: 10.1089/scd.2019.0301
Sun D, Yang L, Zheng W, Cao H, Wu L, Song H. Protective effects of bone marrow mesenchymal stem cells (bmmscs) combined with normothermic machine perfusion on liver grafts donated after circulatory death via reducing the ferroptosis of hepatocytes. Med Sci Monit. 2021;27:e930258.
pubmed: 34112750
pmcid: 8204680
doi: 10.12659/MSM.930258
Wu L, Cao H, Tian X, Zheng W, Yuan M, Li X, et al. Bone marrow mesenchymal stem cells modified with heme oxygenase-1 alleviate rejection of donation after circulatory death liver transplantation by inhibiting dendritic cell maturation in rats. Int Immunopharmacol. 2022;107:108643.
pubmed: 35240383
doi: 10.1016/j.intimp.2022.108643
Verstegen MMA, Mezzanotte L, Ridwan RY, Wang K, de Haan J, Schurink IJ, et al. First report on ex vivo delivery of paracrine active human mesenchymal stromal cells to liver grafts during machine perfusion. Transplantation. 2020;104(1):e5–7.
pubmed: 31609902
doi: 10.1097/TP.0000000000002986